Nasdaq

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...
Nasdaq

Purple Biotech presents data for tri-specific antibody platform CAPTN-3

Purple Biotech (PPBT) announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European Organization for Research and Treatment of Cancer, National ...
Seeking Alpha

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...
Seeking Alpha

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...
Business Insider

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated ...
Business Insider

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the ...
FOX8 Cleveland

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio, Inc ...